ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022

A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma.

Anita D'Souza et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.